1[1]Hospers CAP,Eisanhauer EA,Vries de EGE.The sulfhydryl containing compounds WR- 2721 and glutathione as radio- and chemoprotective agents.A review,indications for use and prospects[J].Br J Cancer,1999,80(5- 6):629- 638.
2[2]Hensley ML,Schuchter LM,Lindley C,et al.American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants[J].J Clin Oncol,1999,171(10):3333- 3353.
4[4]Schuchfer LM,Meropot,Glick JH.Radition and chemotherapy protectors[A].devita Jr VT,Hellman S,Rosenberg SA.Cancer principles ＆ practice of oncology[M].5th ed.Philadelphia,New york: Lippincott Raven Publishers,1997.3087- 3089.
5[5]Capizzi RL.The preclinical basis for broad spectrum selective cytoprotection of normal tissue from cytotoxic therapies by amifostine[J].Semin Oncol,1999,26(2 suppl 7):3- 21.
6[6]Snyder RD,Grdina DJ.Further evidence that the radioprotect aminothiol,WR 1065,catalyticallay inactivates mammalian topoisomerase Ⅱ [J].Cancer Res,2000,60(5):1186- 1188.
7[7]Trog D,Bank P,Wendt TG,et al.Daily amifostine given concomitantly to chemoradiation in head and neck cancer.A pilot study[J].Strahlenther Onkol,1999,175(9):444- 449.
8[8]Wasserman T,Mackowiak JI,Brizel DM,et al.Effect of amifostine on patients assessed clinical benefit in irradiated head and neck cancer[J].Int J Radiat Oncol Biol Phys,2000,48(4):1035- 1039.
9[9]elvaggi G,Belani CP.Carboplatin and paclitaxel in non small cell lung cancer:the role of amifostine[J].Semin Oncol,1999,26(2 suppl 7):51- 60.
10[10]Gridelli C,Guida C,Barletta B,et al.Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer:a phase Ⅰ study[J].Lung Cancer,2000,29(2):131- 137.
